127 related articles for article (PubMed ID: 34585447)
1. Zeylenone synergizes with cisplatin in osteosarcoma by enhancing DNA damage, apoptosis, and necrosis via the Hsp90/AKT/GSK3β and Fanconi anaemia pathway.
Yang S; Xiao H; Sun Y; Cao L
Phytother Res; 2021 Oct; 35(10):5899-5918. PubMed ID: 34585447
[TBL] [Abstract][Full Text] [Related]
2. Zeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways.
Zhang L; Huo X; Liao Y; Yang F; Gao L; Cao L
Sci Rep; 2017 May; 7(1):1669. PubMed ID: 28490807
[TBL] [Abstract][Full Text] [Related]
3. Zeylenone Induces Mitochondrial Apoptosis and Inhibits Migration and Invasion in Gastric Cancer.
Yang S; Liao Y; Li L; Xu X; Cao L
Molecules; 2018 Aug; 23(9):. PubMed ID: 30150551
[TBL] [Abstract][Full Text] [Related]
4. Anti-ganglioside GD2 monoclonal antibody synergizes with cisplatin to induce endoplasmic reticulum-associated apoptosis in osteosarcoma cells.
Zhu W; Mao X; Wang W; Chen Y; Li D; Li H; Dou P
Pharmazie; 2018 Feb; 73(2):80-86. PubMed ID: 29442009
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis.
Liu L; Geng H; Mei C; Chen L
Oxid Med Cell Longev; 2021; 2021():6661534. PubMed ID: 33859780
[TBL] [Abstract][Full Text] [Related]
6. Zeylenone represses the progress of human prostate cancer by downregulating the Wnt/β‑catenin pathway.
Zeng S; Zhu B; Zeng J; Wu W; Jiang C
Mol Med Rep; 2018 Dec; 18(6):5572-5578. PubMed ID: 30365080
[TBL] [Abstract][Full Text] [Related]
7. Proteasome Inhibitor MG132 Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells and Inhibits Tumor Growth.
Sun F; Zhang Y; Xu L; Li S; Chen X; Zhang L; Wu Y; Li J
Oncol Res; 2018 May; 26(4):655-664. PubMed ID: 29191257
[TBL] [Abstract][Full Text] [Related]
8. Podocalyxin promotes cisplatin chemoresistance in osteosarcoma cells through phosphatidylinositide 3-kinase signaling.
Huang Z; Huang Y; He H; Ni J
Mol Med Rep; 2015 Sep; 12(3):3916-3922. PubMed ID: 26017117
[TBL] [Abstract][Full Text] [Related]
9. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
10. Downregulated Long Non-Coding RNA MSC-AS1 Inhibits Osteosarcoma Progression and Increases Sensitivity to Cisplatin by Binding to MicroRNA-142.
Zhang L; Zhao G; Ji S; Yuan Q; Zhou H
Med Sci Monit; 2020 Mar; 26():e921594. PubMed ID: 32155139
[TBL] [Abstract][Full Text] [Related]
11. The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis.
Davaadelger B; Perez RE; Zhou Y; Duan L; Gitelis S; Maki CG
Cancer Biol Ther; 2017 Nov; 18(11):895-903. PubMed ID: 28696156
[TBL] [Abstract][Full Text] [Related]
12. miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.
Zhou Y; Huang Z; Wu S; Zang X; Liu M; Shi J
J Exp Clin Cancer Res; 2014 Jan; 33(1):12. PubMed ID: 24468065
[TBL] [Abstract][Full Text] [Related]
13. Caffeine citrate enhanced cisplatin antitumor effects in osteosarcoma and fibrosarcoma in vitro and in vivo.
Abe K; Yamamoto N; Hayashi K; Takeuchi A; Tsuchiya H
BMC Cancer; 2019 Jul; 19(1):689. PubMed ID: 31307409
[TBL] [Abstract][Full Text] [Related]
14. Anticancer potential of TUG1 knockdown in cisplatin-resistant osteosarcoma through inhibition of MET/Akt signalling.
Zhou Q; Hu T; Xu Y
J Drug Target; 2020 Feb; 28(2):204-211. PubMed ID: 31305159
[TBL] [Abstract][Full Text] [Related]
15. The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.
Ui T; Morishima K; Saito S; Sakuma Y; Fujii H; Hosoya Y; Ishikawa S; Aburatani H; Fukayama M; Niki T; Yasuda Y
Oncol Rep; 2014 Feb; 31(2):619-24. PubMed ID: 24317439
[TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibitory effects of capsaicin combined with cisplatin on human osteosarcoma in culture and in xenografts.
Wang Y; Deng X; Yu C; Zhao G; Zhou J; Zhang G; Li M; Jiang D; Quan Z; Zhang Y
J Exp Clin Cancer Res; 2018 Oct; 37(1):251. PubMed ID: 30326933
[TBL] [Abstract][Full Text] [Related]
17. Poncirin downregulates ATP-binding cassette transporters to enhance cisplatin sensitivity in cisplatin-resistant osteosarcoma cells.
Zhao L; Zhang W; Zhang F
Phytother Res; 2021 Jan; 35(1):278-288. PubMed ID: 32779800
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional regulation of Runx2 by HSP90 controls osteosarcoma apoptosis via the AKT/GSK-3β/β-catenin signaling.
Liang GH; Liu N; He MT; Yang J; Liang ZJ; Gao XJ; Rahhal AH; He QY; Zhang HT; Zha ZG
J Cell Biochem; 2018 Jan; 119(1):948-959. PubMed ID: 28681940
[TBL] [Abstract][Full Text] [Related]
19. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin.
Bagatell R; Beliakoff J; David CL; Marron MT; Whitesell L
Int J Cancer; 2005 Jan; 113(2):179-88. PubMed ID: 15455381
[TBL] [Abstract][Full Text] [Related]
20. EZH2 promotes the progression of osteosarcoma through the activation of the AKT/GSK3β pathway.
Wan D; Han X; Zhang C; Zhang Y; Ma Y; Wang G
Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1179-1186. PubMed ID: 35818168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]